The Impact of Nasogastric Tube Gastric Decompression on Postoperative Nausea and Vomiting in Orthognathic Surgery
Launched by NOVA SCOTIA HEALTH AUTHORITY · May 15, 2024
Trial Information
Current as of February 18, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how the use of a nasogastric tube (a thin tube inserted through the nose into the stomach) affects the chances of experiencing nausea and vomiting after corrective jaw surgery, also known as orthognathic surgery. The goal is to see if having this tube helps reduce nausea and vomiting in patients during the first 24 hours after their surgery.
To participate in this study, you need to be at least 16 years old and scheduled for orthognathic surgery at Victoria General Hospital. This includes surgeries to correct jaw alignment, such as single-jaw or double-jaw procedures. However, if you are under 16, pregnant, or have certain health conditions that might affect your stomach's ability to empty, you won’t be eligible. If you join the trial, you can expect to be monitored for nausea and vomiting after your surgery to help researchers understand the impact of the nasogastric tube on your recovery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients over the age of 16 at the time of consent undergoing orthognathic surgery for the correction of dentofacial deformities at the Victoria General Hospital during the study period.
- Orthognathic surgery to include:
- • 1. Patients who receive single-jaw surgery (i.e. BSSO \[Bilateral Sagittal Split Osteotomy\] only, or LeFort only).
- • 2. Patients receiving double-jaw surgery (i.e. BSSO and LeFort).
- • 3. Patients undergoing a functional genioplasty in addition to another osteotomy (i.e. BSSO and/or LeFort).
- Exclusion Criteria:
- * Patients will be excluded if they do not meet inclusion criteria or if they have risk factors known to directly impact PONV and/or cause delayed gastric emptying:
- • 1. Patients under the age of 16 at the time of consent.
- • 2. Patients contraindicated to undergo elective surgery, including pregnant patients.
- • 3. Patients undergoing a functional genioplasty procedure only.
- • 4. Patients taking GLP-1 receptor agonists).
- • 5. Patients with known gastroparesis.
Trial Officials
James Brady, DDS/MD
Principal Investigator
NSHA
About Nova Scotia Health Authority
The Nova Scotia Health Authority (NSHA) is a leading healthcare organization dedicated to enhancing the health and well-being of individuals and communities across Nova Scotia, Canada. As the largest provider of health services in the province, NSHA is committed to advancing clinical research and innovation through rigorous clinical trials that aim to improve patient care and outcomes. With a focus on collaboration, NSHA engages healthcare professionals, researchers, and patients to address pressing health challenges and contribute to the global body of medical knowledge. By fostering a culture of evidence-based practice and continual improvement, NSHA plays a pivotal role in shaping the future of healthcare delivery in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Halifax, Nova Scotia, Canada
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0